Reimbursed Care Access in Saint Pierre and Miquelon

Currently classified as a strictly controlled substance under French national drug-scheduling laws (applied to Saint Pierre and Miquelon as a French collectivity), with no authorized medical use outside of approved clinical research. French law treats possession, manufacture and supply of substances classed as "stupéfiants" as criminal offences and criminal penalties apply; medical/therapeutic use is only possible within formal, approved clinical trials or exceptional regulatory pathways. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Routine therapeutic/clinical access is not available in France (and thus not available in Saint Pierre and Miquelon) except through formal, regulatory‑approved clinical trials or experimental programmes. #

Esketamine (registered as SPRAVATO® in France) is an authorized medicinal product for specific treatment‑resistant depression indications and is subject to conditional reimbursement and strict clinical-use restrictions. The French High Authority for Health (HAS) issued advice supporting maintained reimbursement in combination with an SSRI/SNRI for adults under 65 with severe, treatment‑resistant depressive episodes who have not responded to at least two different oral antidepressants in the current episode; HAS documents explicitly define the eligible population and clinical positioning of esketamine and set the grounds for reimbursement decisions. #

Regulatory and practical points important for Saint Pierre and Miquelon (as French territory): administration must follow national marketing‑authorization (AMM) and ANSM/ HAS guidance, be delivered under medical supervision in appropriate healthcare settings (certified centres/clinics), and prescribing/dispensing and monitoring rules are those defined at the national level for France. Reimbursement levels and conditions follow the French social security / national health insurance framework as implemented for all French territories; HAS opinions and ANSM decisions determine the scope, and local hospitals/clinics must comply with prescription, monitoring and reporting conditions outlined by these bodies. #

Ketamine is an established medical anaesthetic in France and is authorized for human (and veterinary) medical use, but preparations are listed among substances controlled as "stupéfiants" with strict prescription, storage and traceability requirements; its use outside licensed medical contexts is illegal. Injectable ketamine preparations are regulated under the stupéfiants framework and require secure prescriptions/record‑keeping; in clinical psychiatry in France, use of racemic ketamine or compounded ketamine for depression is considered off‑label and is generally provided under hospital (specialised) protocols rather than as a reimbursed outpatient drug. # #

Practically, where ketamine is used for psychiatric indications in France it is typically delivered in supervised hospital settings or specialised clinics under controlled protocols; because the majority of psychiatric ketamine uses are off‑label, broad public reimbursement under the standard national drug reimbursement lists is not generally available — exceptions depend on specific hospital activity funding and case‑by‑case arrangements. Prescription, distribution and monitoring are governed by ANSM/Ministry of Health frameworks applicable across French territories (including Saint Pierre and Miquelon). #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, manufacture and supply are prohibited except within supervised, approved research contexts. #

Currently classified as a strictly controlled substance under national drug-scheduling laws, with no authorized medical use outside of approved clinical research. There is no routine clinical or reimbursed pathway for therapeutic use in France or its collectivities. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Therapeutic claims (for addiction treatment) are not recognized in routine French healthcare and access would only be via approved research protocols. #

Preparations containing DMT or other scheduled alkaloids are treated as "stupéfiants" and are therefore strictly controlled; consumption, possession or distribution of ayahuasca brews is illegal outside of specific, approved scientific research contexts. There is no recognized reimbursed medical pathway. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Peyote/mescaline preparations are therefore prohibited except under formal research authorisations. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Synthetic phenethylamine derivatives (2C family) fall under the national controls on psychotropic/stupefiant substances. # #